CALGARY, May 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (‘Oncolytics’) today announced the appointment of Ed Levy, PhD, to Oncolytics’ Board of Directors.
“Through his senior management positions at QLT, Dr. Levy has had extensive experience in establishing, developing and building alliances with major pharmaceutical companies, as well as playing a significant role in building QLT into a major biotechnology company in Canada,” said Dr. Brad Thompson, President and CEO of Oncolytics.
Upon retiring from QLT in late 2002, Dr. Levy became an adjunct professor at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. From 1988 to 2002, Dr. Levy was with Vancouver-based biotechnology company QLT Inc., most recently as Senior Vice President from 1998. In these roles, he was primarily responsible for negotiating and managing QLT’s strategic alliances, led strategic planning and oversaw the company’s intellectual property. Dr. Levy served on the board of BIOTECanada from 1999-2002, and he has served on the boards of several technology companies and not-for-profits. Dr. Levy holds a PhD in the History and Philosophy of Science from Indiana University and taught philosophy of science at UBC from 1967-1988.
“Oncolytics is developing a very promising approach for cancer treatment,” said Dr. Levy. “I am pleased to be working with Oncolytics to further develop REOLYSIN(R).”
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation. For further information about Oncolytics, please visit www.oncolyticsbiotech.com
Oncolytics Biotech Inc.
CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW,Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,cathy.ward@oncolytics.ca, www.oncolyticsbiotech.com; The Equicom Group,Nick Hurst, 20 Toronto Street, Toronto, Ontario, M5C 2B8, Tel: (416)815-0700 ext.226, Fax: (416) 815-0080, nhurst@equicomgroup.com; TheInvestor Relations Group, Damian McIntosh, 11 Stone St, 3rd Floor, NewYork, NY, 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,dmcintosh@investorrelationsgroup.com; RenMark Financial Communications,John Boidman, 2080 Rene Levesque Blvd. W., Montreal, PQ, H3H 1R6, Tel:(514) 939-3989, Fax: (514) 939-3717, jboidman@renmarkfinancial.com
